This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | LOE date |
|---|---|---|---|
| Tecentriq | Hoffmann-La Roche Ltd. | For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations. | 2026-05-25 |
| Cabometyx | Ipsen Biopharmaceuticals Canada, Inc. | For the treatment of locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (nPNET). | 2026-05-29 |
| Elfabrio | Chiesi Canada Corporation | Fabry Disease | 2026-06-09 |
| Spevigo | LEO Pharma Inc. | generalized pustular psoriasis (GPP) | 2026-02-03 |
| Solufy | psychotic disorders, mood disorders, and major depressive disorder | 2026-06-03 | |
| Quillivant ER | KYE Pharmaceuticals Inc. | Attention-deficit/hyperactivity disorder (ADHD) | 2026-05-21 |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | LOE date | LOI date |
|---|---|---|---|---|
| Okedi | Bausch Health, Canada Inc. | Schizophrenia in Adults | 2026-03-16 | 2026-05-25 |
| Itovebi | Hoffmann-La Roche Ltd. | In combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor-positive (HR+) (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment. | 2026-02-18 | 2026-05-26 |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
| Title | Manufacturer | Indication | LOE date | Close date |
|---|---|---|---|---|
| Skyclarys | Biogen Canada Inc. | Friedreich's ataxia | 2025-08-21 | 2026-06-10 |
| Zepzelca | Jazz Pharmaceuticals Canada Inc. | For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy. | 2026-02-25 | 2026-06-03 |
| Longavo | Teva Canada Innovation | Schizophrenia in Adults | 2025-11-03 | 2026-05-29 |
| TBD | Sun Pharma Canada Inc. | Multiple Indications | 2026-05-12 |
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.